Cerevance Media Center
Solengepras Leads the Shift Beyond Dopamine
Current News
January 9, 2023
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
- CVN766 was well tolerated with no serious adverse events
- CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
- Data supports once a day dosing of CVN766 in future studies
November 30, 2022
Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
- Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
- Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
- Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
August 9, 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
April 19, 2022
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
News Archive
October 7, 2026
Cerevance to Present Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
- Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2
- Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia and motor experiences of daily living (MDS-UPDRS Part II)
- Improvements in daytime sleepiness (Epworth Sleepiness Scale) and quality of life (PDQ-39, exploratory) point to broad motor and non-motor benefit
- Generally well tolerated, with fewer adverse events than those typically associated with dopaminergic adjunctive therapies, and a discontinuation rate similar to placebo
- Cerevance to meet with FDA to discuss the path to a potential New Drug Application
February 23, 2026
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
December 1, 2025
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
November 24, 2025
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
Events Archive
October 30, 2026

A Binding Site for CVN293 Reveals a Mechanism for Allosteric Control of THIK-1 K2P Channel Gating
February 4, 2026

Discovery of Potent, Selective and Brain-Penetrant Small Molecule CD38 Inhibitors
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021




